A Phase 3 interventional study of Technosphere Insulin and Metformin & Secretagogues in Diabetes Mellitus, Type 2, sponsored by Mannkind Corporation. Completed at 120 sites in 11 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-10-16.
Sponsored by Mannkind Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 — none open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 2.
Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is one of 5 that started in 2004, is one of 25 in phase 3, and was the 7th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 26 · Phase 4 7
First in 1999; this study’s year is marked. 5 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 547 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 129 across the 49 interventional studies. Of the 46 that completed or were terminated, 11 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 49 have an industry lead sponsor. The 10 most frequent:
Mannkind Corporation is the lead sponsor of 57 studies on the registry; 3 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.
23 studies in Diabetes Mellitus, Type 2 by Mannkind Corporation: none open now, none under way, none of them phase 3. Of 22 finished, 10 (45%) have results posted.
Among the 23 studies in Diabetes Mellitus, Type 2 by Mannkind Corporation, this one is the 3rd largest by enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2004, is one of 9 in phase 3, and was the 3rd registered.
Mannkind Corporation’s Diabetes Mellitus, Type 2 studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Mannkind Corporation’s 23 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
to demonstrate the efficacy of inhaled Technosphere/Insulin in combination with metformin versus combination metformin and a secretagogue
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Technosphere Insulin
Drug: Technosphere Insulin
Metformin \& Secretagogues
Drug: Metformin & Secretagogues
Technosphere \& Metformin
Drug: Technosphere Insulin & Metformin
Inhalation, 15U/30U, prandial
Drug page: Metformin
Metformin tablets,Secretagogues supplied as any of the currently marketed brands and formulations.
Technosphere Insulin Inhalation Powder 15U/30U, Metformin tablets
Difference in Change From Baseline for HbA1c Between TI+ Metformin and Metformin+Secretagogue
Time frame: Baseline to Week 12
Difference in Change From Baseline for HbA1c Between TI Alone and Metformin+Secretagogue
(Change from baseline within TI Alone) minus (change from baseline within metformin + secretagogue)
Time frame: Baseline to Week 12
Change in HbA1c From Baseline to Week 24 (Subjects Who Stayed on Original Treatment)
Time frame: Week 24
31 May 2006 (first subject enrolled) to 03 Mar 2008 (last subject completed. Multi-national trial conducted in Argentina, Brazil, Canada, Chile, Czech Republic, Mexico, Poland, Russian Federation, Spain, Ukraine, and USA.
| Milestone | TI Inhalation Powder Alone | Metformin & Secretagogues | TI Inhalation Powder + Metformin |
|---|---|---|---|
| Started | 183 | 170 | 175 |
| Completed | 133 | 152 | 119 |
| Not completed | 50 | 18 | 56 |
| Withdrew: Adverse event | 8 | 2 | 6 |
| Withdrew: Physician decision | 13 | 2 | 10 |
| Withdrew: Withdrawal by subject | 21 | 10 | 20 |
| Withdrew: Various | 4 | 0 | 20 |
| Withdrew: Lost to follow-up | 1 | 3 | 0 |
| Withdrew: Protocol violation | 3 | 1 | 0 |
| Milestone | TI Inhalation Powder Alone | Metformin & Secretagogues | TI Inhalation Powder + Metformin |
|---|---|---|---|
| Started | 29 | 72 | 254 |
| Completed | 27 | 70 | 233 |
| Not completed | 2 | 2 | 21 |
| Withdrew: Adverse event | 0 | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 3 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 2 | 8 |
| Withdrew: Various | 0 | 0 | 5 |
| Percentage of total hemoglobin | Metformin & Secretagogues | TI Inhalation Powder + Metformin |
|---|---|---|
| Difference in Change From Baseline for HbA1c Between TI+ Metformin and Metformin+Secretagogue | -0.78 ± -0.78 | -0.70 ± -0.70 |
(Change from baseline within TI Alone) minus (change from baseline within metformin + secretagogue)
| Percentage of total hemoglobin | TI Inhalation Powder Alone | Metformin & Secretagogues |
|---|---|---|
| Difference in Change From Baseline for HbA1c Between TI Alone and Metformin+Secretagogue | 0.12 ± 1.3 | -0.76 ± 0.92 |
| percentage of total hemoglobin | TI Inhalation Powder Alone | Metformin & Secretagogues | TI Inhalation Powder + Metformin |
|---|---|---|---|
| Change in HbA1c From Baseline to Week 24 (Subjects Who Stayed on Original Treatment) | -1.82 ± 1.114 | -1.23 ± 1.080 | -1.68 ± 1.014 |
Collected over From first dose until 30 days after last dose of study medication. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TI Inhalation Powder Alone | — | 5/181 (2.8%) | 72/181 (39.8%) |
| Metformin & Secretagogues | — | 5/166 (3%) | 42/166 (25.3%) |
| TI Inhalation Powder + Metformin | — | 11/351 (3.1%) | 138/351 (39.3%) |
| Event | TI Inhalation Powder Alone | Metformin & Secretagogues | TI Inhalation Powder + Metformin |
|---|---|---|---|
| ATRIAL FIBRILLATIONCardiac disorders | 0/181 | 2/166 | 0/351 |
| SUPRAVENTRICULAR TACHYCARDIACardiac disorders | 0/181 | 1/166 | 0/351 |
| CELLULITISInfections and infestations | 0/181 | 1/166 | 0/351 |
| LOWER LIMB FRACTUREInjury, poisoning and procedural complications | 0/181 | 1/166 | 0/351 |
| DUPUYTREN'S CONTRACTUREMusculoskeletal and connective tissue disorders | 0/181 | 1/166 | 0/351 |
| BLADDER NECK OBSTRUCTIONRenal and urinary disorders | 0/181 | 1/166 | 0/351 |
| URETHRAL STRICTURERenal and urinary disorders | 0/181 | 1/166 | 0/351 |
| ANGINA PECTORISCardiac disorders | 0/181 | 1/166 | 0/351 |
| HYPOGLYCAEMIAMetabolism and nutrition disorders | 1/181 | 0/166 | 2/351 |
| RETROPERITONEAL HAEMORRHAGEGastrointestinal disorders | 1/181 | 0/166 | 0/351 |
| Event | TI Inhalation Powder Alone | Metformin & Secretagogues | TI Inhalation Powder + Metformin |
|---|---|---|---|
| COUGHRespiratory, thoracic and mediastinal disorders | 49/181 | 6/166 | 62/351 |
| HYPOGLYCAEMIAMetabolism and nutrition disorders | 24/181 | 21/166 | 84/351 |
| NASOPHARYNGITISInfections and infestations | 4/181 | 13/166 | 18/351 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 7/181 | 12/166 | 8/351 |
| Age, Continuous(years) | TI Inhalation Powder Alone | Metformin & Secretagogues | TI Inhalation Powder + Metformin | Total |
|---|---|---|---|---|
| Mean | 57.3 (26 to 75) | 57.6 (18 to 75) | 56.8 (37 to 77) | 57.2 (18 to 77) |
| Sex: Female, Male(Participants) | TI Inhalation Powder Alone | Metformin & Secretagogues | TI Inhalation Powder + Metformin | Total |
|---|---|---|---|---|
| Female | 93 | 88 | 101 | 282 |
| Male | 84 | 74 | 68 | 226 |
| Body Weight(kilograms) | TI Inhalation Powder Alone | Metformin & Secretagogues | TI Inhalation Powder + Metformin | Total |
|---|---|---|---|---|
| Mean | 86.1 ± 15.6 | 84.2 ± 16.2 | 83.9 ± 13.9 | 84.8 ± 15.27 |
| Fasting Plasma Glucose(milligrams per deciliter) | TI Inhalation Powder Alone | Metformin & Secretagogues | TI Inhalation Powder + Metformin | Total |
|---|---|---|---|---|
| Mean | 193.5 ± 52.4 | 194.6 ± 48.5 | 188.6 ± 49.7 | 192.2 ± 50.23 |
| HbA1c(percentage) | TI Inhalation Powder Alone | Metformin & Secretagogues | TI Inhalation Powder + Metformin | Total |
|---|---|---|---|---|
| Mean | 8.9 ± 0.95 | 8.9 ± 0.94 | 9.0 ± 0.97 | 8.9 ± 0.95 |
Showing the first 100 of 120 sites across 11 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2004 and a primary completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 6 years 7 months after primary completion. A results delay was requested in Jun 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin, Regular, Human